全文获取类型
收费全文 | 201887篇 |
免费 | 2780篇 |
国内免费 | 77篇 |
专业分类
耳鼻咽喉 | 1461篇 |
儿科学 | 7386篇 |
妇产科学 | 3563篇 |
基础医学 | 19950篇 |
口腔科学 | 2174篇 |
临床医学 | 15071篇 |
内科学 | 35805篇 |
皮肤病学 | 1107篇 |
神经病学 | 19104篇 |
特种医学 | 9928篇 |
外国民族医学 | 1篇 |
外科学 | 32802篇 |
综合类 | 2649篇 |
一般理论 | 20篇 |
预防医学 | 20342篇 |
眼科学 | 3243篇 |
药学 | 11591篇 |
中国医学 | 656篇 |
肿瘤学 | 17891篇 |
出版年
2022年 | 208篇 |
2021年 | 553篇 |
2020年 | 307篇 |
2019年 | 563篇 |
2018年 | 22463篇 |
2017年 | 17772篇 |
2016年 | 19926篇 |
2015年 | 1475篇 |
2014年 | 1643篇 |
2013年 | 1900篇 |
2012年 | 8718篇 |
2011年 | 22673篇 |
2010年 | 19718篇 |
2009年 | 12396篇 |
2008年 | 21026篇 |
2007年 | 23249篇 |
2006年 | 2196篇 |
2005年 | 3822篇 |
2004年 | 4886篇 |
2003年 | 5678篇 |
2002年 | 3791篇 |
2001年 | 706篇 |
2000年 | 866篇 |
1999年 | 623篇 |
1998年 | 515篇 |
1997年 | 436篇 |
1996年 | 278篇 |
1995年 | 294篇 |
1994年 | 281篇 |
1993年 | 217篇 |
1992年 | 267篇 |
1991年 | 302篇 |
1990年 | 351篇 |
1989年 | 316篇 |
1988年 | 302篇 |
1987年 | 251篇 |
1986年 | 235篇 |
1985年 | 244篇 |
1984年 | 203篇 |
1983年 | 188篇 |
1982年 | 150篇 |
1981年 | 151篇 |
1980年 | 160篇 |
1979年 | 168篇 |
1978年 | 146篇 |
1977年 | 123篇 |
1975年 | 120篇 |
1973年 | 140篇 |
1971年 | 122篇 |
1970年 | 123篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
Heung Bae Kim James J Pomposelli Craig W Lillehei Roger L Jenkins Maureen M Jonas Laura E Krawczuk Steven J Fishman 《Liver transplantation》2005,11(11):1389-1394
Extrahepatic portal vein thrombosis (EHPVT) may occur in children or adults and usually comes to clinical attention due to complications of portal hypertension such as variceal hemorrhage. A variety of standard surgical techniques exist to manage these patients, but when these fail surgical options are limited. We describe two novel portosystemic shunts that utilize the gonadal vein as an autologous conduit. Four patients were evaluated for EHPVT with variceal bleeding. None of the patients were candidates for a standard splenorenal shunt due to prior surgical procedures. The first patient underwent a left mesogonadal shunt and the remaining 3 patients underwent a right mesogonadal shunt. Postoperative ultrasound or computed tomography (CT) scan confirmed early patency of the shunt in each patient. There have been no further episodes of variceal hemorrhage with follow-up of 3.5 years in the child who underwent the left mesogonadal shunt, and 17, 19, and 20 months in the patients who underwent the right mesogonadal shunt. Three of the 4 shunts remain patent. One shunt thrombosis occurred in a patient homozygous for the Factor V Leiden mutation despite anticoagulation with coumadin. This is the first report of the successful use of the gonadal vein as an in situ conduit for constructing a portosystemic shunt. In conclusion, the right and left mesogonadal shunts may be useful as salvage operations for patients with EHPVT who have failed standard surgical shunt procedures. 相似文献
52.
53.
54.
Pilar Nicolás 《Hereditary cancer in clinical practice》2007,5(3):144-152
The specific characteristics of genetic data lead to ethical-legal conflicts in the framework of genetic diagnosis. Several international organisations, including UNESCO and the Council of Europe, have enacted rules referring to the use of genetic information. This paper discusses possible legal and ethical criteria that could be used in genetic testing. 相似文献
55.
P M Schulz S C Schulz S C Goldberg P Ettigi R J Resnick R O Friedel 《The Journal of nervous and mental disease》1986,174(8):457-463
Relatives of 22 schizotypal probands were evaluated for lifetime psychiatric diagnoses. Forty-four (N = 44) of the 97 available relatives were interviewed directly using the Diagnostic Interview Schedule. The rates of psychiatric diagnoses were compared with those of sixty-six (N = 66) of 140 relatives of 30 depressed patients. Family history of mental illness was ascertained by the informant method on the remainder of relatives of both proband groups. The rate of depression found in the relatives of schizotypal patients was 52% in those directly interviewed and 25.7% when informants' reports on unavailable relatives are pooled with direct interview data. These rates were not significantly higher than those found for the relatives of depressed probands (34.8% by direct interview and 21% including reports from informants). The high rates of depression in the relatives of schizotypal probands may indicate that schizotypal personality is associated with affective disorder and not only with schizophrenia. However, the high rates may be due to the presence of depressive character traits in relatives, which inflate the rates of dysthymic disorder and other chronic depressive disorders in the relatives of borderline patients. 相似文献
56.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
57.
58.
59.
Sergio Barroilhet Adrián Cano-Prous Salvador Cervera-Enguix Maria João Forjaz Francisco Guillén-Grima 《Social psychiatry and psychiatric epidemiology》2009,44(12):1051-1065
Introduction
This paper presents the results of a study on the psychometric properties of an authorized Spanish version of the McMaster Family Assessment Device, a self-report measure of family functioning. 相似文献60.